title: Initial treatment of transplant candidates with multiple myeloma.
abstract: Over the last decade, thalidomide, bortezomib, and lenalidomide have been introduced into the armamentarium of myeloma therapies. These novel agents have improved the rate of complete remission both before and after autologous stem cell transplantation (ASCT) without substantially increasing toxicity, which has important implications as the achievement of high-quality responses is a significant prognostic factor for outcome. This review will focus on the most recent results of novel agent-based induction therapies, as well as on interesting developments in the transplant phase that are aimed at improving the results of conditioning regimens.
authors.affiliation: Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France. Electronic address: philippe.moreau@chu-nantes.fr.
authors.forename: Philippe
authors.initials: P
authors.lastname: Moreau
authors.forename: Cyrille
authors.initials: C
authors.lastname: Touzeau
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D019317:Evidence-Based Medicine; D006801:Humans; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000188:drug therapy / Q000628:therapy*; D011379:Prognosis; D011719:Pyrazines / Q000627:therapeutic use; D012074:Remission Induction; D033581:Stem Cell Transplantation; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D000077269:Lenalidomide